Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
Alnylam Pharmaceuticals
ALNY
Market cap
$61.6B
Overview
Fund Trends
Analyst Outlook
Journalist POV
470.27
USD
+0.91
0.19%
At close
Updated
Oct 15, 4:00 PM EDT
Pre-market
After hours
470.27
0.00
0%
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
0.19%
5 days
4.27%
1 month
1.98%
3 months
51.15%
6 months
103.64%
Year to date
101.3%
1 year
63.65%
5 years
226.71%
10 years
450.15%
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
45.5%
Negative
Positive
Neutral
Negative
Positive
Zacks Investment Research
11 hours ago
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
Zacks Investment Research
12 hours ago
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Positive
Zacks Investment Research
yesterday
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
yesterday
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
Here is how Alnylam Pharmaceuticals (ALNY) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
Neutral
Benzinga
4 days ago
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
Positive
Zacks Investment Research
14 days ago
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Neutral
Business Wire
14 days ago
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), a global Phase 3 cardiovascular outcomes trial (CVOT) designed to evaluate the potential of zilebesiran, an investigational biannual subcutaneously administered RNAi therapeutic, to reduce the risk of major adverse cardiovascular (CV) events in patients w.
Neutral
Business Wire
17 days ago
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Data from a post hoc analysis of the HELIOS-B.
Negative
Investors Business Daily
19 days ago
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.
Positive
Zacks Investment Research
21 days ago
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close